|
Oct 9
|
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
|
|
Sep 3
|
Avenue Therapeutics to Participate in Upcoming Investor Conferences
|
|
Jun 20
|
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Mar 11
|
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
|
|
Jan 16
|
Sidoti Events, LLC's Virtual January Micro-Cap Conference
|
|
Jan 11
|
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|
|
Jan 5
|
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
|
|
Jan 4
|
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
|
|
Dec 1
|
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
|
Nov 13
|
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
|
|
Nov 6
|
Avenue Therapeutics' US$4.5m Market Cap Fall Books Insider Losses
|
|
Nov 2
|
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
|
|
Oct 31
|
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
|
|
Aug 10
|
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|